A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis.
By G. D'Haens, W. Sandborn, B. Feagan, K. Geboes, S. Hanauer, E. Irvine, M. Lémann, P. Marteau, P. Rutgeerts, J. Schölmerich and 1 more. Gastroenterology, 2007
1,217 citations recorded by the source corpus.
Subfields: Epidemiology, Genetics, Surgery
View Paper: https://www.semanticscholar.org/paper/4aefb32c39214899e4e95c4aa73718dd4c98e13c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Genetics
Citations in the corpus
- ACG Clinical Guideline: Ulcerative Colitis in Adults (2019, background): “In a prospective comparison, the PUCAI, SCCAI, and partial Mayo score demonstrated the best validity and responsiveness (51,53,54).”
- Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. (2012, neutral): “Rectosigmoid 14/46 (30) 13/30 (43) 9/32 (28) 7/31 (23) 18/46 (39)”